Company Presentations
The deadline to submit applications has already passed. If you would like to be put on the waiting list, please contact Mat Laquoi at +49 89 2388 756 43 or mlaquoi@ebdgroup.com.
The selected presenting companies will be published end of August.
Presentation tracks
Presenting at BIO-Europe is the most direct way to get your innovative asset or idea directly in front of the right audience.
Biotech Company Presentation
In this track, biotech companies can partner their products, initiate strategic alliances and tap into the global financing network.
Midsize Pharma Presentation
This track reflects increased demand for midsize pharma presentations. Find your perfect fit partners.
Next Generation Presentation
This track is the most direct way for early stage projects and small entrepreneurial companies to get their innovative asset or idea directly in front of potential partners.
Academic Innovators Presentation
Academic researchers and technology transfer offices can apply to present their asset or idea to funding and development partners
Questions?
We are happy to help. Please contact:
Matias Laquoi | EBD Group+49 89 2388 756 43 | mlaquoi@ebdgroup.com
Want to improve your presentation and business development skills?
These hands-on, practical courses are an ideal opportunity to boost your presentation and business development skills right before BIO-Europe.
WHY PRESENT AT BIO-EUROPE?
Increase your company's visibility and generate interest among 3,800+ executives from over 60 countries
Pitch your company to top-tier VCs, pharma and private equity investors
Put your licensable asset on the opportunity map
The Selection Committee made up of industry experts:
Bayer – Mark Wolters, VP, Head of Early Licensing
Biotechnology Innovation Organization (BIO) – Bernard V. Fallon, Director, Industry Research
FHR Consult – Fritz Rudert, General Manager
Gemini Advisors – Wendy Johnson
Novartis – Charles Bailey, Head of Neurosciences BD &L
Novo Nordisk – Tomas Landh, Innovation Sourcing VP, Senior Principal Scientist
TVM Capital Life Science – Daniel Parera, Executive-in-Residence
Make sure that you open your talk/presentation with the most important thing you want your audience to know.
Donna L. LaVoie
President and CEO
LaVoie Group
Less is more: The more clear and concise the presentation, the more memorable it will be. Save the details for the Q&A session.
Carin Canale-Theakston
President
Canale Communications
Start and end your presentation with why your audience should be interested by clearly and concisely describing the value and potential of the product/technology and why it is different from others out there. This will help to "hook" them in the beginning, and it will be the last thing they remember. Include supporting data in the middle, but don't overdo it.
Michelle Linn
President
Linnden Communications
Unless you are trying to sell your whole company, focus 90 percent of your presentation only on the asset(s) you are trying to partner and don't forget to include the clinical utility.
Doug MacDougall
President
MacDougall Biomedical Communications, Inc.
Presenting companies must tell a compelling story to grab the interest of investors/partners. Much like a movie, if the plot (vision/objectives) has no action (milestones), and the characters (drug technology/pipeline) aren't brought to life (strong messages, visually appealing presentation), then those in the audience will not care.
Gregory Q. Tiberend
President and CEO
Tiberend Strategic Advisors, Inc.
For more information, contact:
Matias Laquoi
EBD Group
+49 89 2388 756 43